Conley Chee - Oct 6, 2022 Form 4/A - Amendment Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Chief Commercial Officer
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Stock symbol: SYRS
Transactions as of: Oct 6, 2022
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 10/11/2022, 04:55 PM
Date Of Original Report: Oct 11, 2022
Previous filing: Feb 17, 2022
Next filing: Oct 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Stock Option (right to buy)	Award	$0	+44.5K		$0.00	44.5K	Oct 6, 2022	Common Stock	44.5K	$6.73	Direct	F1
transaction	SYRS	Restricted Stock Units	Award	$0	+34K		$0.00	34K	Oct 6, 2022	Common Stock	34K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.
F2	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3	These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

Remarks:

This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct a typographical error in the "Date of Earliest Transaction" reported on behalf of the reporting person on October 11, 2022. Exhibit 24: Power of Attorney